New drug approved for irritable bowel, chronic constipation

(HealthDay)—Linzess (linaclotide) has been approved by the U.S. Food and Drug Administration to treat forms of chronic constipation that don't respond to traditional treatment, and irritable bowel syndrome accompanied by constipation, the agency said Thursday in a news release.

The National Institutes of Health estimates that some 63 million people are affected by chronic constipation, and about 15.3 million have (IBS), the FDA said.

Linzess is taken once daily on an empty stomach, at least 30 minutes before the first meal. The most frequently noted adverse reaction is diarrhea.

The drug's label contains a boxed warning that it shouldn't be taken by people aged 16 or younger, the FDA said.

Linzess is produced by Cambridge, Mass.-based Ironwood Pharmaceuticals.


Explore further

FDA OKs Amitiza for treatment of IBS-C

More information: Medline Plus has more about constipation.

Copyright © 2012 HealthDay. All rights reserved.

Citation: New drug approved for irritable bowel, chronic constipation (2012, August 30) retrieved 18 September 2019 from https://medicalxpress.com/news/2012-08-drug-bowel-chronic-constipation.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more